AU2001266902A1 - High throughput screening of compounds for biological activity - Google Patents

High throughput screening of compounds for biological activity

Info

Publication number
AU2001266902A1
AU2001266902A1 AU2001266902A AU6690201A AU2001266902A1 AU 2001266902 A1 AU2001266902 A1 AU 2001266902A1 AU 2001266902 A AU2001266902 A AU 2001266902A AU 6690201 A AU6690201 A AU 6690201A AU 2001266902 A1 AU2001266902 A1 AU 2001266902A1
Authority
AU
Australia
Prior art keywords
biological activity
compounds
target
candidate compound
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266902A
Other languages
English (en)
Inventor
Jill Elaine Haizlip
Diane Michele Ignar
Channa K Jayawickreme
Holly Kay King
James Arthur Liacos
Kirsten Mills
Jason J. Ruan
Howard Ray Sauls Jr.
Joel Edward Shaffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001266902A1 publication Critical patent/AU2001266902A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001266902A 2000-06-13 2001-06-13 High throughput screening of compounds for biological activity Abandoned AU2001266902A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21126800P 2000-06-13 2000-06-13
US60/211,268 2000-06-13
US29453101P 2001-05-30 2001-05-30
US60/294,531 2001-05-30
PCT/US2001/019033 WO2001096597A2 (en) 2000-06-13 2001-06-13 High throughput screening of compounds for biological activity

Publications (1)

Publication Number Publication Date
AU2001266902A1 true AU2001266902A1 (en) 2001-12-24

Family

ID=26906001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266902A Abandoned AU2001266902A1 (en) 2000-06-13 2001-06-13 High throughput screening of compounds for biological activity

Country Status (8)

Country Link
US (1) US20030219825A1 (de)
EP (1) EP1360495B1 (de)
JP (1) JP2004503249A (de)
AT (1) ATE359513T1 (de)
AU (1) AU2001266902A1 (de)
DE (1) DE60127867T2 (de)
ES (1) ES2284655T3 (de)
WO (1) WO2001096597A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008212A1 (en) * 2003-04-09 2005-01-13 Ewing William R. Spot finding algorithm using image recognition software
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007100618A2 (en) * 2006-02-23 2007-09-07 Atto Bioscience Novel cell-based phosphodiesterase assays
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
CN101949819B (zh) * 2010-09-16 2013-05-01 北京优纳科技有限公司 一种基于图像识别的细胞计数方法
KR20180117529A (ko) 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
WO2018194406A1 (ko) * 2017-04-19 2018-10-25 주식회사 프로티나 단백질-단백질 상호작용 분석 방법 및 장치

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
US5670113A (en) * 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
AU2953295A (en) * 1994-07-01 1996-01-25 W.R. Grace & Co.-Conn. Hepatocyte test kit
JPH11504507A (ja) * 1995-03-31 1999-04-27 ノボ ノルディスク アクティーゼルスカブ 生物学的に活性な基質を、生きている細胞に関するこれらの影響によって同定するための方法
US5780258A (en) * 1996-09-04 1998-07-14 Tularik, Inc Drug screens for regulators of the expression of the obese gene
GB2338711B (en) * 1997-11-27 2000-11-15 Max Planck Gesellschaft Identification and characterization of interacting molecules
US5976813A (en) * 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening
AU6048599A (en) * 1998-09-18 2000-04-10 Cellomics, Inc. A system for cell-based screening
AU2001265092A1 (en) * 2000-06-02 2001-12-17 Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries

Also Published As

Publication number Publication date
EP1360495B1 (de) 2007-04-11
ATE359513T1 (de) 2007-05-15
ES2284655T3 (es) 2007-11-16
JP2004503249A (ja) 2004-02-05
DE60127867T2 (de) 2008-01-17
WO2001096597A2 (en) 2001-12-20
EP1360495A2 (de) 2003-11-12
DE60127867D1 (de) 2007-05-24
US20030219825A1 (en) 2003-11-27
WO2001096597A3 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
WO2003036256A3 (en) Method and apparatus for increasing the dynamic range and accuracy of binding assays
AU6834700A (en) Device and method for determining multiple analytes
DK1495330T3 (da) Fremgangsmåde til at identificere forbindelser, som påvirker transmembran-proteiner
WO2008022205A3 (en) Thyroxine-containing compound analysis methods
BR9813307A (pt) Dispositivo e métodos para determinação de analisado em uma solução
WO2000012123A3 (de) Verfahren und messeinrichtung zur bestimmung einer vielzahl von analyten in einer probe
EP1325343A4 (de) Erhöhung des durchsatzes in einem automatischen klinischen analysierer durch aufteilen von assays nach typ
DE59814441D1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
DE60001406T2 (de) Apparat und methode zur präzisen lokalisierung von reaktionsplatten
WO2004011607A3 (en) Reagent and method for determination of a substance using an immunoaggregator
AU2849300A (en) Methods and assay kits for detecting mononuclear cell phenotype
CA2342767A1 (en) Multihued labels
ES8801440A1 (es) Un metodo de ensayo mejorado para la determinacion de analitos bioligicos tales como haptenos, antigenos ,receptores , farmacos y similares.
AU4299800A (en) Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample
WO1999055913A3 (en) Reduced complexity nucleic acid targets and methods of using same
WO2001096597A3 (en) High throughput screening of compounds for biological activity
WO2000070342A3 (en) Optical system analysis of cells
AU5572998A (en) Improving performance of binding assays by use of more than one label
WO2009064006A1 (ja) γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法
FR2817349B1 (fr) Nouveau procede de criblage de modulateurs de la transcription bacterienne
CA2542825A1 (en) Multimer sample pretreatment and immunoassay without boiling, for total adiponectin assessment
ATE513058T1 (de) Verdrängungsassay zur detektion von nukleinsäureoligomer-hybridisierungsereignissen
WO2004013607A3 (en) Methods, devices and kits for multiplex blotting of biological samples from multi-well plates
AU2002312899A1 (en) Hybrid method for the production of carriers for analyte determination
AU5649499A (en) Method of detecting thiol-containing compound